Search

Calmare NJ USA

Tag

cancer pain therapy

Seniors Living with Chronic Pain Benefit from Scrambler Therapy

March 14, 2018

We don’t want anyone to live with pain–but it’s especially disheartening to see older people forced to battle neuropathy during their golden years, often as a result of:

  • Nerve damage (small fiber neuropathy)
  • Diabetic neuropathy (chronic foot pain)
  • Pain from cancer or chemotherapy treatment (CIPN)
  • Post-surgical pain
  • Chronic back pain
  • Phantom limb syndrome

Since we introduced Calmare Therapy in 2011, we have helped older people reduce or even eliminate their neuropathic pain, after a myriad of prescription pain medications and other traditional therapies failed.

Recently, Bernice Goldman made the trip up from Florida with her daughter, who discovered Dr. Cooney’s success using scrambler therapy through online research.

Bernice was suffering from small fiber neuropathy and had tried every medication, every therapy and every treatment, without success. She explains below:

Mrs. Goldman is one of several seniors who reaped the rewards of FDA-cleared Calmare Therapy, which is a painless treatment with no side effects.

Peter Hinninger Battled #CRPS for 17 Years and Won the War with Calmare
“Peter’s Foot” is available on Amazon.com. Click on the image to go to Amazon.
Author and Calmare Therapy NJ USA Patient Peter Hinninger

 

 

 

 

 

 

 

 

Eighty-seven-year-old Ann Shares Her Pain Relief Story (below):
A Letter from Nelia B Who Traveled to NJ from Amsterdam for CIPN Relief After Chemo Taxol Therapy

“For the past two and a half years I’ve been suffering from severe CIPN in my feet, after undergoing Taxol therapy for breast cancer. Three months after finishing the chemo, the neuropathy got much worse.

Since then I’ve been on a high dose of pain medication (Gabapentin, Venlafaxine, Tramadol). Still, my pain kept being at a level between 5 to 10. I also tried morphine patches, two painful and unsuccessful nerve blocks, cortisone injections, acupuncture, tens treatments and vitamin B12 shots. Nothing helped.

My doctors told me that my CIPN was chronic and not much else could be done about it.

Meanwhile, I kept researching options and read about the clinical trials for CIPN with “Calmare Therapy” at the Massey Cancer Center, as well as at the University of Wisconsin (UW) Carbone Center.

The doctors at both institutions told me that they experienced positive outcomes. I was also able to talk to a patient who underwent Calmare treatment, which was encouraging. Then in the fall of 2011, I learned that the U.S. Military opened several Calmare centers.

I decided to give it a try and contacted Dr. Cooney at the Rutherford Allied Medical Group in the United States.”

Read Nelia’s full story and treatment outcome here.

Do You or an Older Loved One Suffer from Treatment-Resistant Chronic Pain?

If the diagnosis is neuropathy, scrambler therapy may be a viable pain management solution which can:

  • Lessen or eliminate chronic pain
  • Improve or restore mobility
  • Reduce or eliminate the need for debilitating prescription pain medication
  • Dramatically improve daily quality-of-life

We invite you to reach out to talk one-on-one about you or your loved one’s medical history and pain management goals.

Complete the info card below or call our respectful and friendly Calmare team at (201) 933-4440 between 10 am and 6 pm EST.

You can also email us at CalmareNJ@gmail.com, where our clinical director, Dr. Michael Cooney, will respond to your message personally within 48 hours.

 

Medscape reports on another positive clinical trial using Calmare for cancer pain

medscapeAnother Calmare Therapy clinical trial, conducted with people battling neuropathic pain as a result of chemotherapy treatment, has again shown  positive patient outcomes (significant lessening of pain) according to a new report published this week by Medscape, an affiliate of WebMD. (You have to register to read the article, but the process is free, quick and easy).

clinical trialCalmare Trial Key Points / Excerpts:

  • Scrambler therapy was not originally developed for the treatment of cancer-related neuropathic pain. Rather, it was developed for chronic pain and, indeed, has been used in many patients with noncancer-related pain, including low back pain.
  • Regardless of the type of neuropathic pain being treated, scores on the 11-point Numerical Rating Scale (NRS) decreased significantly from baseline to 1-month follow-up (P < .001).
  • The need for ‘rescue opioids’ dropped from a baseline dose of 5 mg to 0 mg at the end of the study.
  • No adverse side effects (“events”) that could have been associated with the therapy were reported.
  • A research team from the Massey Cancer Center at Virginia Commonwealth University in Richmond reported similar findings using the same cutaneous electro-stimulation device (scrambler therapy) for CIPN (J Pain Symptom Manage. 2010;40:883-891).
  • Some patients relapsed, but re-treatment and maintenance therapy (booster treatments) provided relief and, again, no adverse effects from treatment were observed.
  • Charles Loprinzi, MD, PhD, from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a trial with 37 CIPN patients and achieved similar study outcomes (Support Care Cancer. 2015 23:943-951).
  • Dr. Loprinzi stated that people have been slow to explore scrambler therapy use because “it sounds too good to be true…” He also reported to Medscape that efforts to conduct larger trials are ongoing, but it takes time and money to perform these trials.

The European Journal of Oncology Nursing also published an abstract of the study reported by Medscape.


More scrambler therapy clinical study news: American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) completed a clinical trial on the benefits of scrambler therapy to be presented June 1:

“Scrambler therapy appears to have a promising effect on post herpetic neuropathy (PHN) with prompt and continued relief and no side effects.” PHN is a chronic, painful burning condition affecting nerve fibers and skin.

Why is this important?

Continued independent clinical trial studies confirm that Calmare scramber therapy offers substantial and ongoing relief from several sources of chronic pain, including cancer and chemotherapy-related treatment.

Abstract:

Background: Post herpetic neuropathy (PHN) is common in cancer and hematologic malignancy patients. It can be debilitating and difficulty to treat effectively. Scrambler therapy, a patient-specific neurocutaneous stimulation device, can be effective in treating chemotherapy induced neuropathy (JPSM 2010) and other neuropathic pain (JPSM 2012).

Methods: We treated ten patients, 2 with cancer as their primary diagnosis, with refractory PHN Scrambler therapy at two institutions. Scrambler therapy was given as 30 minute sessions daily for 10 days. Pain was recorded before and after treatment.

Results: The patient mean age was 54 ± SD 13 years, 6 men and 4 women, with a mean duration of PHN for 15.6 months (range 2.5 to 48 months) without satisfactory relief despite conventional drugs. The average pain score rapidly diminished from 7.64 ± 1.46 at baseline to 0.42 ± 0.89 at one month, a 95% reduction, with continued relief at 2 and 3 months. Patients achieved maximum pain relief with less than 5 treatments.

Conclusions: Scrambler therapy appears to have a promising effect on PHN, with prompt and continued relief and no side effects. Further research is warranted.

Mayo Clinical Trial using Calmare scrambler therapy for study

February 2, 2012

The Mayo Clinic is still posting for study participants to engage in scrambler therapy treatment for chronic pain in patients with rash from Varicella Zoster Virus infection. To learn more, visit http://clinicaltrials.mayo.edu/clinicaltrialdetails.cfm?trial_id=101568

Dr. Cooney to appear on “RSD and You” December 19 at 3 p.m.

Dr. Michael Cooney of Rutherford Allied Medical Group will appear for the third time on Joseph Aquilino’s “RSD and You” BlogTalk radio program today at 3 p.m. (New York time). Dr. Cooney will be talking about his practice’s latest findings administering Calmare Pain Therapy Treatment for patients with RSD and fibromyalgia. Additionally, he has just successfully completed treatment with a patient suffering for chronic pain as a result of chemotherapy treatment (CIPN). He will also discuss his new Calmare clinical study for patients living with chronic pain as a result of multiple sclerosis, starting in January 2012 in Rutherford, NJ. Please visit our Facebook page for program details.

Chemotherapy-induced peripheral neuropathy (CIPN) patient begins Calmare Therapy

As we mentioned a few weeks ago, we welcomed our first Calmare Therapy patient from Europe (Amsterdam) this week who is undergoing treatment to combat chronic bilateral foot pain as a result of chemotherapy-induced peripheral neuropathy, or CIPN. As we and others have shared in the past, CIPN pain is notoriously difficult to treat successfully.

Our patient contracted CIPN three months after undergoing chemotherapy for breast cancer more than three years ago.  Her pain level escalated to a seven and she began having difficulty walking. She is undergoing 10 Calmare treatments and her outcome looks very positive. We look forward to sharing her outcome as she therapy progresses.

Dr. Michael Cooney

Treatment for Chemotherapy Pain – Calmare Therapy Making News

By Dr. Michael J. Cooney

It is one of the great frustrations of healthcare–pain.  And, often, those who suffer the most live every moment of every day in pain. This could not be more true for cancer patients who have endured chemotherapy in order to eradicate the cancer from their bodies. Often, the chemo is successful and the patient’s cancer is in remission. But these “soldiers against cancer” are often left with a weakened, damaged body as a result of the powerful after-affects of the drugs.

This condition, chemotherapy-induced peripheral neuropathy, called CIPN, has no real cure. There are pain killing drugs (more drugs) of course, along with a few alterative therapies can help alleviate some of the pain. But there is no cure for CIPN.

That’s why the news from several studies underway, including the University of Wisconsin, as well as the Mayo Clinic (3/4 way through this video, Dr. Charles Loprinzi discusses the scrambler therapy study which they have in progress now 11.2011)  are so important. These centers’ studies are finding that Calmare’s scrambler therapy is producing significantly positive results in minimizing or even eliminating pain from chemotherapy treatment. These findings, starting to filter in from our country’s most respected cancer centers, serve as a light at the end of a long, dark tunnel of pain for our friends, family and colleagues living with the painful after-effects of chemotherapy treatment.

CDC reports deaths by painkiller overdose an “epidemic”

By Dr. Michael J. Cooney

While prescriptions for pain medication continues to skyrocket, more and more of our friends, colleagues, neighbors and family are dying from accidental overdoses. While this heartbreaking news is very difficult for those of us working in pain management to hear, it also reinforces the urgent need for alternative methods to combat chronic pain. Medications are not the solution to chronic pain in many, many cases.

Often, when we first meet new Calmare patients, they present us with heavy bags filled with bottle after bottle of powerful drugs. In addition, these patients are often physically debilitated by using these medications, of which many are considered “narcotic”.

After 30 years of treating good people living in constant pain, I have seen firsthand that Calmare Therapy can alleviate pain in people who have been suffering for more than a year, three, even 10 years. Calmare has no debilitating side effects and is far less expensive that prescription drugs. It’s a solution that the rest of our country must learn about. And we will continue to spread the word–patient by patient until these sad statistics are just a distant memory.

Blog at WordPress.com.

Up ↑

%d bloggers like this: